The Myeloproliferative Neoplasms Channel is supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2023 | Consistency of pacritinib in patients with MF: pooled analysis from PERSIST-1 & PERSIST-2
In this video, Prithviraj Bose, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses the efficacy of pacritinib in patients with myelofibrosis (MF) based on findings from a pooled analysis of the PERSIST-1 and PERSIST-2 trials (NCT01773187; NCT02055781). Dr Bose first shares some background information on this agent, and then explains that the results of this analysis demonstrate that pacritinib is consistently effective in patients with myelofibrosis (MF) regardless of cytopenias. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
